European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration “At Biogen Idec, our commitment ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Biogen Idec Canada Inc today announced AVONEX ® PEN ™ is now available for patients with relapsing multiple sclerosis (MS) and patients with a single ...
-- First single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX recommended for approval in the European Union and authorised in Canada -- AVONEX PEN is designed ...
WESTON, Mass. — The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug. Biogen Idec said the FDA ...
March 2, 2012 — The US Food and Drug Administration (FDA) has approved a new autoinjector system and titration regimen for patients receiving once-a-week treatment with interferon beta-1a (Avonex, ...
Biogen Idec saw revenue rise 18% in the second quarter to $1.4 billion amid strong sales of Avonex, with a host of promising late-stage pipeline products waiting in the wings. Revenues from the firm’s ...
Biogen Idec ( BIIB) recently announced the submission of a new drug application (NDA) for its oral multiple sclerosis candidate, BG-12. The NDA was based on data from the phase III DEFINE and CONFIRM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results